About
Overview
Leadership Team
Board of Directors
Scientific Advisory Board
Contact Us
Science
Unique Nanotechnology
Addressing Neuronal Imbalances
Benefits of Our Approach
Partnership Opportunities
Pipeline
Overview
RNS60
Amyotrophic Lateral Sclerosis (ALS)
Stroke
Discovery Programs
News
Press Releases
Publications & Presentations
Careers
Culture
Open Positions
Connect with us
info@revalesio.com
FROM PRESS
to presentations
News
FEBRUARY 23, 2021
REVALESIO SIGNS AGREEMENT TO DESIGN TRIAL WITH RNS60 FOR THE HEALEY ALS PLATFORM TRIAL
JANUARY 4, 2019
FDA 2 GRANTS REVALESIO FAST TRACK STATUS FOR ALS INVESTIGATIONAL DRUG RNS60
MARCH 6, 2018
RNS60 PROMOTES MYELINATION OF NANOFIBERS BY OLIGODENDROCYTES
All news
Publications
June 2020
RNS60 HAS THERAPEUTIC EFFECTS IN A MOUSE MODEL OF TRAUMATIC BRAIN INJURY (TBI)
March 2019
RNS60 TREATMENT WAS WELL TOLERATED IN AN OPEN LABEL CLINICAL PILOT STUDY IN ALS
June 2018
RNS60 INCREASES PRODUCTION OF NEW FUNCTIONAL MITOCHONDRIA IN NEURONAL CELLS
All Publications
